Bicycle Therapeutics (NASDAQ:BCYC) Shares Break Above 50-Day Moving Average – Time to Sell?

Bicycle Therapeutics PLC Sponsored ADR (NASDAQ:BCYC) passed above its 50-day moving average during trading on Monday. The stock has a 50-day moving average of $3.75 and traded as high as $3.84. Bicycle Therapeutics shares last traded at $3.77, with a volume of 590,237 shares changing hands.

Analyst Upgrades and Downgrades

BCYC has been the topic of several research reports. Weiss Ratings reiterated a “sell (e+)” rating on shares of Bicycle Therapeutics in a report on Friday, October 2nd. Needham & Company LLC decreased their price objective on shares of Bicycle Therapeutics from $15.00 to $14.00 and set a “buy” rating for the company in a research note on Thursday, July 30th. Zacks Research downgraded shares of Bicycle Therapeutics from a “hold” rating to a “strong sell” rating in a report on Wednesday, October 14th. Jefferies Financial Group reaffirmed a “buy” rating and issued a $10.00 price objective on shares of Bicycle Therapeutics in a report on Thursday, October 29th. Finally, Wall Street Zen upgraded shares of Bicycle Therapeutics from a “sell” rating to a “hold” rating in a research note on Saturday, October 31st. Five investment analysts have rated the stock with a Buy rating, three have assigned a Hold rating and two have given a Sell rating to the stock. According to MarketBeat, Bicycle Therapeutics has an average rating of “Hold” and an average price target of $13.57.

Bicycle Therapeutics Price Performance

The company has a fifty day moving average price of $3.74 and a 200-day moving average price of $4.46.

Bicycle Therapeutics (NASDAQ:BCYC) last posted its earnings results on Thursday, October 29th. The company reported ($0.15) EPS for the quarter, topping the consensus estimate of ($0.40) by $0.25. The firm had revenue of $34.06 million for the quarter, compared to analyst estimates of $12.22 million. Bicycle Therapeutics had a negative return on equity of 26.02% and a negative net margin of 169.75%. Sell-side analysts expect that Bicycle Therapeutics PLC Sponsored ADR will post -2.11 earnings per share for the current year.

Institutional Investors Weigh In On Bicycle Therapeutics

A number of hedge funds and other institutional investors have recently made changes to their positions in BCYC. R Squared Ltd acquired a new stake in Bicycle Therapeutics during the third quarter valued at $98,000. Alps Advisors Inc. raised its position in shares of Bicycle Therapeutics by 30.1% in the third quarter. Alps Advisors Inc. now owns 66,501 shares of the company’s stock worth $245,000 after acquiring an additional 15,379 shares during the period. Vontobel Holding Ltd. raised its position in shares of Bicycle Therapeutics by 15.0% in the third quarter. Vontobel Holding Ltd. now owns 23,000 shares of the company’s stock worth $85,000 after acquiring an additional 3,000 shares during the period. Portland Investment Counsel Inc. purchased a new stake in shares of Bicycle Therapeutics during the 2nd quarter worth about $64,000. Finally, Marquette Asset Management LLC purchased a new stake in shares of Bicycle Therapeutics during the 2nd quarter worth about $309,000. Institutional investors and hedge funds own 86.15% of the company’s stock.

About Bicycle Therapeutics

Bicycle Therapeutics plc is a biopharmaceutical company that develops medicines using its proprietary Bicycle molecule technology. Bicycle molecules are small, constrained peptides designed to bind selectively to biological targets while offering characteristics that may support tissue penetration, rapid clearance, and chemical synthesis. The company is primarily focused on creating therapies for cancer and other serious diseases. Bicycle Therapeutics’ research programs include targeted therapeutics intended to deliver cytotoxic payloads to tumor cells, as well as immune-modulating treatments designed to activate or direct the immune system within the tumor microenvironment.